, Sleep-wake, cognitive and clinical correlates of treatment outcome with repetitive transcranial magnetic stimulation for young adults with depression, Psychiatry Research (2018), doi: https://doi.org/10.1016/j.psychres. 2018.12.002 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Better cognitive flexibility, verbal learning, later age of onset and greater number of depressive episodes were associated with better treatment outcome. There were no other significant/trend-level associations. rTMS had no effect on sleep-wake or cognitive measures. We provide the first evidence for the utility of cognitive flexibility and verbal learning in predicting rTMS outcome in depressed young adults. This research provides preliminary support for rTMS as an early intervention for depression and supports the need for sham-controlled trials.
Introduction
An earlier age of illness onset (Allen et al., 2007) and a greater number of depressive episodes (Berwian et al., 2017; Bockting et al., 2015) are robust predictors of recurrence and relapse of depression. The delivery of treatments early in the course of illness results in better response outcomes and can prevent onset of chronic illness (Lee et al., 2012; McGorry et al., 2006) . To this end, developing and evaluating optimal early intervention strategies for depression is imperative.
High-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) is efficacious for refractory depression (Kedzior and Reitz, 2014 ) and preliminary research is now emerging to show that rTMS may be effective as an early intervention for youth depression (Bloch et al., 2008; Huang et al., 2012; Wall et al., 2011) . Response rates in clinical trials of rTMS for treatment-resistant depression range from 30% (Berlim et al., 2013) to 50% (Ren et al., 2014) and identifying predictors of response is critical to reduce the burden (in terms of time and expense) of non-response on individuals and services. Efforts towards understanding this variability in chronic depression have been growing and have largely focused on using neurophysiology and imaging to identify predictors of response (Arns et al., 2012; Fox and Pascual-Leone, 2012; Weigand et al., 2018) . However, there is a paucity of investigations into the utility of clinical (e.g., illness chronicity, sleep-wake/circadian changes) and cognitive features (e.g., episodic memory) in predicting rTMS treatment outcome for depression. Furthermore, this type of research has not yet been extended to adolescent or young adult depression populations, an important step towards evaluating rTMS as an early intervention approach.
Sleep-wake disturbance is among the most common symptoms of depression (Benca et al., 1992) .
In mood disorders, sleep disturbance corresponds with poorer pharmacological and psychosocial treatment outcomes (Manglick et al., 2013) and, often persists even when mood symptoms have remitted (Geoffroy et al., 2014; van Mill et al., 2010) . Whether sleep-wake disturbance can be normalised by rTMS treatment or has utility in informing rTMS treatment outcomes for depression ACCEPTED MANUSCRIPT
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Page 5 is unclear. Effects of rTMS treatment in this regard remains equivocal, with rTMS being linked to improved sleep Nishida et al., 2017; Pellicciari et al., 2013) as well as having no effect on sleep (Antczak et al., 2017; Brakemeier et al., 2008; Lowe et al., 2013; Rosenquist et al., 2013) . Notably, most of these investigations are limited by the use of symptomatic sleep data rather than objective measures of sleep-wake behaviour. Three studies have, however, utilised polysomnography (Pellicciari et al., 2013) or actigraphy (Antczak et al., 2017; Nishida et al., 2017) to investigate the effect of rTMS treatment for depression on sleep-wake behaviour. No change in sleep-wake variables were noted in these studies (Antczak et al., 2017; Nishida et al., 2017) , except for one finding of a trend-level improvement with rTMS in wakefulness after sleep onset (Pellicciari et al., 2013) . These studies included older cohorts with mean ages of 45 years or older, a potential reason for the null findings given that sleep-wake disruption is age related in mood disorders. Specifically, younger people with mood disorders present with delayed sleep-wake patterns, more sleep disturbance and poorer consolidation of sleep compared with older people, suggestive of different aberrations in underlying circadian processes across depressive age groups (Robillard et al., 2013; Robillard et al., 2014) . As such, further evaluation of objective sleep-wake measures as potential predictors of rTMS treatment response for depression is required.
Similarly, the utility of cognition in informing outcomes of rTMS treatment for depression has not been comprehensively investigated. However, rTMS-associated improvements in cognition reportedly occur prior to any improvements in mood and are predictive of favourable rTMS outcome for chronic depression (Hoy et al., 2012) . Typically, cognitive deficits are apparent before or at the time of illness onset (Lee et al., 2012) and we have previously shown that neuropsychological functioning is a robust predictor of longitudinal functioning, over and above symptomatology, in young psychiatric patients (Lee et al., 2013) . Given this, evaluating the association between cognitive functioning and improvements in depression following rTMS in young people may be important, in terms of predictive utility. Of note, improvements in cognition
with rTMS treatment for depression have been frequently demonstrated in chronic patients (Hoy and Fitzgerald, 2010) and more recently, in adolescents (Huang et al., 2012; Wall et al., 2013) .
Commensurate with cognitive deficits, impaired psychosocial functioning in depression (which is subserved by cognitive, emotional and social cognitive elements) can often persist despite symptomatic recovery and is associated with long term prognosis (Knight and Baune, 2017; Tohen et al., 2000) . Despite that recovery of psychosocial functioning has been understudied in the rTMS depression literature, small to moderate improvements in quality of life have been noted with rTMS (Dumas et al., 2012) . Evaluating psychosocial functioning change in addition to symptom change with rTMS would provide a more global assessment of recovery of depression and is of particular significance in adolescents or young adults people given the importance of educational and occupational performance in this patient group.
There are some data suggesting that rTMS treatment may be more effective at early illness stages of depression rather than at chronic stages. A series of studies have reported that younger age is associated with better response in people with depression (Aguirre et al., 2011; Figiel et al., 1998; Fregni et al., 2006; Pallanti et al., 2012; Rostami et al., 2017) . Some of these studies were on older (i.e. 50 years or older) cohorts (Fregni et al., 2006; Pallanti et al., 2012) and for those that compared younger and older groups, the age groups were defined as younger or older than 45 (Aguirre et al., 2011) and, younger or older than 60 (Pallanti et al., 2012) years old. Given that about 50% of people with depression will experience their first episode before 30 years of age (Kessler et al., 2005) , the extant literature is limited in informing whether rTMS may be better targeted to those at early stages of depression. Other work supporting rTMS as an early intervention approach analysed clinical measures of chronicity and severity of illness revealing that better response with rTMS was achieved by those with a later age of onset, shorter duration of illness, lower baseline score of depression (Fitzgerald et al., 2016) and who are less medication refractory (Fregni et al., 2006) . Nevertheless, these studies included chronic depression samples with broad age ranges and it is
unclear whether a similar pattern of associations would be observed in younger, early stage depression patients to whom early interventions would typically be provided for.
The primary objective of the present study was to determine whether sleep-wake and cognitive measures are associated with outcome of rTMS treatment for depression in young adults. In addition, in a young adult sample, we explored the relationship between measures of illness chronicity (i.e. age of onset, duration of illness and number of depressive episodes) and improvements in depression with rTMS. Lastly, we sought to determine if there are improvements in sleep-wake disturbance, cognition and psychosocial functioning with rTMS in addition to improvements in depressive symptoms in a young adult cohort.
Methods

Participants
Participants aged 18 to 30 years old were recruited from a specialised inpatient and outpatient early intervention for mental health problems facility, the Young Adult Mental Health Service at St Vincent's Private Hospital, Sydney, Australia. All participants had a primary diagnosis of a mood (Rush et al., 2003) that was stable over a 2-week period (as determined by weekly QIDS assessments), (ii) failure to respond to a minimum of two adequate trials of antidepressant medication (i.e. at least four weeks of treatment at a therapeutic dose as determined by the study psychiatrist, ES) and, (iii) that medications were stabilised for at least 2 weeks before treatment and throughout the treatment course. Participants were excluded if they were pregnant or lactating, had current psychosis or mania, severe restrictive eating disorders, substance use disorders, a major developmental disorder (e.g. autism), a diagnosis of epilepsy or history of seizure in the last 5 years, any other neurological illness or medical illness impacting brain function, intellectual disability or inability to provide informed consent, a history of a sustained head injury (loss of consciousness for more than 30 minutes), insufficient English for assessment or, a contraindication to MRI scanning and/or TMS including but not limited to the presence of implanted metallic components in the cranium, a pacemaker, cochlear implant, medication pump or other electronic device. No medication changes were permitted during the rTMS treatment course and participants were withdrawn from the trial if their treating psychiatrist determined a medication change was necessary. There were no exclusion criteria relating to type of psychotropic medications used.
Out of the twenty-one participants that were recruited into the study, sixteen participants (mean age = 22 ± 3.9; age range = 18 to 29; 15 females; 12 inpatients) completed the minimum of pretreatment clinical assessment, rTMS treatment and post-treatment clinical assessment. Six participants dropped out of the trial (n=2 became too unwell and required other treatment, n=2 changed their mind, n=1 was unable to sustain inpatient status and, n=1 did not return for posttreatment clinical assessment). One of the participants who dropped out because they were too
unwell, re-entered the trial at a later date. All 16 participants completed pre-and post-treatment neuropsychological assessment. Fourteen completed/had valid pre-treatment actigraphy data, however, only 9 participants completed/had valid post-treatment actigraphy data. Primary diagnosis, comorbid diagnoses and medication list for each participant is shown in Table 1 .
Magnetic Resonance Imaging and Neuronavigation for Site of Stimulation Localisation
Participants underwent MRI scanning on a 3-Tesla GE MR750 Discovery scanner (GE Medical Systems, Milwaukee, WI) with five fiducial markers which were placed on the left and right preauricular points, nasion, inion and vertex. To enable neuroanatomical analysis at high resolution 
Clinical and neuropsychological assessment
Trained research psychologists conducted clinical interviews and neuropsychological assessments (MK, RSCL). Clinical information was collected (i.e. age of onset, duration of illness and number of depressive episodes) and symptom scales were administered during pre-treatment assessment, Symptom scales were, the Hamilton Depression Rating Scale (HDRS, 17-item) (Hamilton, 1967) to quantify depressive symptoms, the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962) to quantify overall psychiatric symptoms and the Social and Occupational Functioning Assessment Scale (SOFAS) to assess psychosocial functioning. The BPRS depression sub-score was empirically derived as a secondary measure of depressive symptoms. Specific cognitive domains assessed in this study were verbal learning and memory (Wall et al., 2013) and, cognitive flexibility (Huang et al., 2012) in keeping with previous reports of cognitive improvements with rTMS in depressed youth. Cognitive flexibility was assessed via the Trail-Making Test, part B (TMT-B) (Franzen et al., 1990) and, verbal learning and memory were assessed by the Rey Auditory Verbal Learning Test (RAVLT) sum of trial 1-5 (RAVLT sum) and 20 min delayed recall (RAVLT A7), respectively (Taylor, 1959) . Neuropsychological variables were converted to demographically corrected z-scores using established norms (Rickert and Senior, 1998 ; Tombaugh al., 1998 ). Each participant was tested using standard and alternate forms of TMT and RAVLT to limit practice effects and the order of form versions were counterbalanced across participants.
Sleep-wake assessment
All participants wore an actigraphy device on their non-dominant wrist for approximately 10 days (GENEActiv, Activinsights, Kimbolton, UK; 50Hz sample rate) and completed a concurrent sleep diary. The number of days with valid data ranged from 5 to 14 days (mean 10.0 ± 2.6 days) for pretreatment assessment and ranged from 6 to 12 days (mean 9.0 ± 2.3 days) for post-treatment assessment. Due to equipment error and data loss, actigraphy data was not able to be analysed for three participants at pre-treatment and six participants at post-treatment. Estimates of sleep onset and offset times were manually scored by trained technicians (JC) using visual inspection and the sleep diaries. This method provides an indirect estimate of sleep, however the terms 'sleep' and 'wake' are used here for descriptive purposes. Estimates of wake during the sleep episode were generated using a previously validated MATLAB program (te Lindert and Van Someren, 2013).
The following sleep-wake parameters were generated: average sleep onset and offset times (timing of the onset and offset of the rest episode) and average wake after sleep onset (WASO: the duration of awakenings during the rest period). 
Statistical Analyses
Results
Change in clinical, sleep-wake and neuropsychological measures with rTMS treatment
The pre-treatment and post-treatment mean and standard deviations for clinical, sleep-wake and neuropsychological variables and pair-wise comparison statistics are shown in Table 2 . Overall, with rTMS treatment, significant improvements in depression and anxiety were found but there were no differences in psychosocial functioning, sleep-wake parameters or cognition. Specifically, significant decreases from pre-treatment to post-treatment assessment were observed for HDRS Table 3 shows the percentage change in HDRS depression scores from pre-to post-treatment. Five participants showed a reduction of 20% or more in HDRS scores and two participants met response criteria (i.e. a reduction of 50% or more in HDRS scores).
Associations between sleep-wake, neuropsychological and clinical patient characteristics and, improvements in psychiatric symptoms
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The correlation matrix of associations between pre-treatment sleep-wake, neuropsychological and clinical measures and, change in symptom score variables is provided in Table 4 . For the sleepwake variables, pre-treatment sleep-onset, pre-treatment sleep-offset and pre-treatment WASO were not significantly associated with change in HDRS total (all p>.05) or change in BPRS depression subscore (all p>.05). A significant positive relationship was observed between pre-treatment neuropsychological variables TMT B (p=.04; see Figure 1 ) and, at the trend-level, RAVLT sum (p=.07; see Figure 2 ) and change in BPRS depression subscore. There was no significant relationship between RAVLT A7 and BPRS depression subscore (p>.05). None of the pre-treatment neurospsycological variables were associated with change in HDRS (all p<.05). Number of depressive episodes (p=.03) and age of onset of psychiatric disorder (at the trend-level; p=.07) but not duration of illness (p>.05) was positively associated with change in BPRS depression subscore (see Figure 3 ). There were no significant correlations between age of onset, duration of illness or number of depressive episodes and change in HDRS scores (all p>.05).
Discussion
This study was the first to examine the utility of key phenotypic features of depression (i.e., sleepwake, cognitive and clinical characteristics) for predicting rTMS treatment outcome in young adults. Depressive symptoms were significantly reduced with rTMS treatment as expected and, for the first time in a youth sample, we provide evidence of a concomitant reduction in anxiety. While rTMS treatment outcome was not related to pre-treatment sleep-wake parameters, it was associated with initial cognitive and clinical features. Specifically, better cognitive flexibility and verbal learning (but not verbal memory) were associated with greater improvements in depression with rTMS. With regards to clinical measures, a later age of onset and greater number of depressive episodes (but not duration of illness) corresponded with better rTMS outcomes. There was no significant effect of rTMS treatment on sleep-wake, cognitive or psychosocial features in the current study.
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The lack of significant correlations between pre-treatment sleep-wake variables and improvement in depression with rTMS is in keeping with previous studies (Brakemeier et al., 2008; Lowe et al., 2013) . Our data suggests that sleep-wake characteristics may not have utility in predicting rTMS treatment response, however, further investigations with larger samples of young depressed adults are needed before any definitive conclusions can be drawn. For a more comprehensive evaluation, it may be useful to specifically recruit samples with atypical depression features characterised by sleep-wake dysregulation. Sleep-wake measures, sleep efficiency, total sleep time and circadian rhythmicity, have previously shown to inform longitudinal clinical outcomes in young people with depression (Robillard et al., 2016) and as such, these measures may be more suited to assessing predictive utility of treatment response and should be considered in future studies. Additionally, the result of no effect of rTMS on objective sleep-wake measures in the current study corroborates previous research (Antczak et al., 2017; Nishida et al., 2017) . It is noteworthy, however, that trendlevel improvements in WASO with rTMS have been reported in chronically depressed patients (Pellicciari et al., 2013 ) and therefore, it is possible that in young depressed samples where aberrant sleep-wake behaviour may be less pronounced, larger samples may be necessary to detect main effects.
We provide the first evidence of a relationship between pre-treatment cognition and improvements in depression with rTMS. These data critically suggest that cognitive functioning may have value in predicting favourable outcome of rTMS treatment for depression and, are consistent with Hoy and colleagues' (2012) observation that initial improvement in cognition with rTMS treatment for depression is associated with response. The cognitive domains we found to be associated with rTMS outcome, cognitive flexibility and verbal learning, have also been shown to improve with rTMS in youth/adolescent depression (Huang et al., 2012; Wall et al., 2013) . This suggests that cognitive flexibility and verbal learning may have particular relevance to rTMS treatment for younger populations. The therapeutic benefit of rTMS for depression is thought to result from ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
Page 15 neurochemical and blood flow changes within the DLPFC as well as extending to functionally connected regions (Noda et al., 2015) . Given the pivotal role of the DLPFC in executive functions and verbal learning, we could speculate that the degree to which the DLPFC and functionally interconnected regions are amenable to neuromodulation may depend on the functional integrity of these regions, providing a potential explanation for the correlation between pre-treatment cognitive measures and rTMS outcome for depression. Nevertheless, we acknowledge that the cognitive impairment in depression is intrinsically and complexly linked to depressive symptoms and the mediating effect of one on the other can often be unclear. However, there was no significant change in cognition with rTMS observed suggesting that the changes in depression with rTMS in this study may be independent of changes in cognition and therefore, may not have influenced the significant relationships between pre-treatment cognition and improvements in depression. Lastly, determining if this relationship is bidirectional and whether targeting cognitive impairment (e.g., using cognitive remediation) could improve response to rTMS to depression would be a valuable next step.
These data showing that a later age of onset and greater number of depressive episodes were associated with greater improvements in depression with rTMS extends previous findings by Fitzgerald and colleagues (2016) from a large, chronic depression sample (n=1132; mean age=46 years). However, we did not find a relationship between duration of illness and change in depression with rTMS unlike the previous study where a shorter duration of illness corresponded with the greatest improvements in depression. The modest sample size and narrow age range in our sample may account for this discrepancy. Our finding that a later age of onset (i.e. less chronic illness) corresponds with greater improvements in depression is somewhat in contrast to the finding that a greater number of episodes (i.e. more chronic illness) corresponds with greater improvements in depression. The age of onset data presented here supports the general consensus that less refractory depression corresponds with better response (Fitzgerald et al., 2016; Fregni et al., 2006; Pallanti et al., 2012) . It is vital to highlight that while clinical measures such as age of onset and number of depressive episodes are easily obtained, clinically useful measures of chronicity, they do
not necessarily reflect the neuropathological stage of illness. Thus, the capacity to make inferences on the relationship between illness chronicity and improvements in depression with rTMS using these measures is limited and further research aiming to elucidate neuropathological changes as disease progresses relative to response to rTMS would be highly valuable as a next step. Moreover, patient-level meta-analyses are likely to provide important insights into the contribution of measures of illness chronicity to response to rTMS for depression, however, there are too few clinical trials on younger, early stage cohorts to allow for this.
The reduction in depression with rTMS treatment in this study is the first to be reported in a young adult cohort and is in keeping with the adolescent (Bloch et al., 2008; Wall et al., 2011) and adult (Kedzior and Reitz, 2014) literature. While it has not been commonly investigated in studies of rTMS for depression, the improvement in anxiety symptoms reported in this research is consistent with previous reports in adults (Fitzgerald et al., 2013; White and Tavakoli, 2015) and adolescents (Bloch et al., 2008) . Critically, our result of no change on measures of verbal learning, verbal memory or cognitive flexibility buttress other evidence that rTMS does not have adverse effects on cognition. Despite reports of improvements in cognition with rTMS (Huang et al., 2012; Wall et al., 2013) , our findings corroborate several clinical trials demonstrating no effect (for review see (Serafini et al., 2015) . It is possible that a more sensitive cognitive battery may have been necessary to detect subtler changes that may be present in early stage depression samples. Similarly, no significant change in measures of psychosocial functioning following rTMS treatment was noted, in contrast with previous studies (Dumas et al., 2012; Janicak et al., 2013) . This difference may be explained by the measure used; due to restrictions on multiple comparisons, we utilised an overall measure of psychosocial functioning whereas the two previous studies more assessed psychosocial functioning by using scales with sub-domains and calculated sub-domain composite scores (i.e.
Medical Outcome Study Short-Form Health Survey and/or EuroQoL 5 Dimension Questionnaire).
The current study is exploratory in nature and as such, limited by issues pertaining to sample characteristics, including a modest sample size. Moreover, due to the modest sample size, it was not possible to covary for inpatient or outpatient status and inpatients are likely to have received the added benefit of residing in an inpatient unit, such as, potentially greater face to face contact and daily schedule regulation. Additionally, cognitive and clinical measures were only associated with change in one measure of depression, the BPRS depression subscore, indicating that the associations may be relevant to specific symptoms of depression better captured in the BPRS subscore than a more comprehensive overall measure of depression. While depression symptoms were reduced with rTMS for several participants (see Table 3 ), a low proportion of approximately 13% met response criteria. Within 11 days of rTMS, 75% of participants had undergone posttreatment assessment and it is possible that we did not capture reduced depressive symptoms of delayed responders. There are reports of reduced response in bipolar patients (Fitzgerald et al., 2016) as well as no difference in response between unipolar and mixed (unipolar and bipolar) samples (Berlim et al., 2014) . Further, there is some indication that patients with comorbidities may show reduced response (Fitzgerald et al., 2016) . As such, it is possible the inclusion of bipolar disorder and patients with comorbidities may have influenced the current findings. Similarly, sixteen participants were on psychotropics and any potential effect of psychotropic use cannot be accounted for in the current study. Notably, the literature on response differences between rTMS as a monotherapy and as an adjunctive therapy is inconsistent (Berlim et al., 2014; Fitzgerald et al., 2016; Slotema et al., 2010) . Lastly, most of our sample were female. It is unclear, however, whether gender is associated with response to rTMS given mixed reports (Huang et al., 2008; Kedzior and Reitz, 2014; Rostami et al., 2017) . Given the aforementioned caveats, the current findings should be interpreted with caution and replication in larger samples is necessary.
In conclusion, by showing reduced depressive and anxiety symptoms and, no cognitive deterioration, this preliminary investigation provides some promising results for rTMS as an early intervention strategy for young adults with depression, warranting sham controlled clinical trials. Critically, this study has identified cognitive flexibility and verbal learning as potential predictors of favourable treatment response in young adults with depression.
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